md-medicaldata

Authors

 

Jovana Drljača¹, Nebojša Janjić¹, Nataša Vučinić², Aleksandra Milutinović³, Milan Popović⁴, Ivan Čapo⁴, Slobodan Sekulić<sup>5

1</sup>Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad
²Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad, Katedra za farmaciju
³Univerzitet u Novom Sadu, Prirodno-matematički fakultet, Departman za biologiju i ekologiju
⁴Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad, Katedra za histologiju i embriologiju
⁵Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad, Katedra za neurologiju

 

UDK: 616.24-006-085

The paper was received / Rad primljen: 12.02.2019.

Accepted / Rad prihvaćen: 21.02.2019.

 

Correspondence to:

Jovana Drljača
University of Novi Sad, Faculty of Medicine,
Hajduk Veljkova 3, 21000 Novi Sad, Serbia,
e-mail: jovana.drljaca@uns.ac.rs

 

 

Sažetak

 

Najčešći tip maligniteta na svetskom nivou jeste karcinom pluća, pri čemu se u većini slučajeva radi o nesitnoćelijskom karcinomu pluća (NSCLC), koji je ujedno i najčešći tip karcinoma pluća kod nepušača. Kod većine pacijenata obolelih od NSCLC, ustanovljeno je prisustvo mutacija u genu za receptor epidermalnog faktora rasta (EGFR). Pored hemioterapije, razvijeno je tri generacije lekova - inhibitora tirozin-kinaza (TKI), koji uspešno deluju pri lečenju NSCLC. Međutim, do danas nije otkriven lek koji je u potpunosti efikasan, s obzirom na pojavu rezistencije kod pacijenata. Bez obzira na veliki broj sprovedenih istraživanja, i dalje postoji velika potreba za istraživanjima koja će se fokusirati na molekularnu osnovu NSCLC povezanog sa EGFR mutacijama.

 

 

Ključne reči:

nesitnoćelijski karcinom pluća, farmakogenetika, receptor epidermalnog faktora rasta, EGFR, pokretačke mutacije

 

 

Abstract

 

Lung cancer is the most common malignant disease worldwide. Non small cell lung carcinoma (NSCLC) is present in the majority of cases and also represents the most common type of lung cancer in non-smokers. Mutations in epidermal growth factor receptor gene (EGFR) are found in most patients diagnosed with NSCLC. Besides chemotherapy, three generations of drugs tyrosine-kinase inhibitors (TKIs) are developed and they have made a success in the treatment of NSCLC. However, up to now no drug was found to be fully efficient due to the constant development of resistance in patients. Despite the great number of conducted studies, there is still a need for further research which will focus on molecular basis of NSCLC associated with EGFR mutations.

 

Key words:

non-small cell lung carcinoma, pharmacogenetics, epidermal growth factor receptor, EGFR, driver mutations

 

 

 

References:

 

1. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Translational Lung Cancer Research. 2015;4:327–38.
2. https://www.who.int/news-room/fact-sheets/detail/cancer, pristupljeno dana 01.02.2018.
3. Institut za javno zdravlje Srbije “Dr Milan Jovanović Batut”. Zdravstveno-statistički godišnjak Republike Srbije 2017. Beograd, 2018.
4. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Advances in Experimental. Medicine and Biology. 2016;893:1–19.
5. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiology, Biomarkers & Prevention. 2016;25:16-27.
6. Alberg AJ, Brock M V, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143:e1S–e29S.
7. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics in Chest Medicine. 2011;4:605-44.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
9. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–24.
10. De S, Ganesan S. Looking beyond drivers and passengers in cancer genome sequencing data. Annals of Oncology. 2017;28:938-945.
11. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L, Lopez-Bigas N. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Scientific Reports. 2013;3:2650.
12. Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation. 2014;94:129–37.
13. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A structural perspective on the regulation of the epidermal growth factor receptor. Annual review of biochemistry. 2015;84:739-64.
14. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–25.
15. Russo A, Franchina T, Ricciardi GRR, Picone A, Ferraro G, Zanhgi M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015;6(29):26814-25.
17. Tsiambas E, Lefas AY, Georgiannos SN, Ragos V, Fotiades PP, Grapsa D, Stamatelopoulos A, Kavantzas N, Patsouris E, Syrigos K. EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review. Pathology, Research and Practice. 2016;212:672–7.
18. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research. 2014;79:34-74.
19. Sriram KB, Larsen JE, Yang IA, Bowman RV, Fong KM.. Genomic medicine in non-small cell lung cancer: paving the path to personalized care. Respirology. 2011;16:257-63.
20. Cooper WA, Lam DCL, O’Tolle SA, Minna JD. Molecular biology of lung cancer. Journal of Thoracic Disease. 2013;5(5):S479–S490.
21. Da Cunha Santos G, Shepher FA, Tsao MS. EGFR Mutations and Lung Cancer. Annual Review of Pathology Mechanisms of Disease. 2011;6:49–69.
22. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology. 2005;23:2513–20.
23. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nagakawa K, Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology. 2010;11:121–8.
24. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology. 2011;29:2866–74.
25. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology. 2015;16(2):141-51.
26. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer 2007;7:169–81.
27. Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. The European Respiratory Review. 2014;23:356–66.
28. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clinical Cancer Research. 2014;20:2249–56.
29. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical Cancer Research. 2011;17:1160–8.
30. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research. 2013;19:2240–7.
31. Wu J-Y, Wu S-G, Yang C-H, Gow C-H, Chang Y-L, Yu C-J, Shih JY, Yang PC. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research. 2008;14:4877–82.
32. Pallan L, Taniere P, Koh P. Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases. Journal of Thoracic Oncology. 2014;9:e75.
33. Grabe T, Lategahn J, Rauh D. C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer? ACS Medicinal Chemistry Letters. 2018;9:779−782.
34. Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T, Iwasawa T, Satoh H, Tamura K, Kasamatsu T, Hayashihara K, Saito T, Takahashi H, Ogura T. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer. 2012;77:64–9.
35. Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, Loeffler JS, Sequist LV, Shaw AT, Shih HA. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with nonsmall cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015;17:296–302.
36. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Grönroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee SM, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom W, Teefe E, Chen SC, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, Swanton C. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346:251–6.
37. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346:256–9.
38. Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, Palmer G, Moro-Sibilot D, Ross JS, Cronin MT, André F, Stephens PJ, Lazar V, Miller VA, Brambilla E. Nextgeneration sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. Journal of Clinical Oncology. 2013;31:2167–72
39. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, Zhou C, Fuerte F, Margono B, Wen W, Tsai J, Truman M, Klughammer B, Shames DS, Wu L.Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical Cancer Research. 2015; 21(14):3196-203.
40. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics. 2017;49(12):1693-1704.
41. Zaric B, Stojsic V, Kovacevic T, Sarcev T, Tepavac A, Jankovic R, Spasic J, Radosavljevic D, Zarogoulidis P, Vukobradovic-Djoric N, Perin B. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma. Journal of Thoracic Oncology. 2014;9:1406–10.
42. Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Diseases. 2013;5(5):S579-92.
43. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. The Lancet Oncology. 2015;16:e342-51.
44. Barber EA, Reckamp KL. Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer. The American Journal of Hematology/Oncology. 2016;12(12):4-7.
45. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. The Journal of the American Medical Association. 2003;290:2149–58.
46. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine. 2005;353(2):123-32.
47. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2004;350:2129–39.
48. Stankov K. Biohemijske i molekularne osnove farmakogenetike. U: Stankov K. Biohemija i genetika naslednih bolesti. Novi Sad: Medicinski fakultet, 2016;228-241.
49. Hirsch FR, Scagliotti G V., Mulshine JL, Kwon R, Curran WJ, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. The Lancet 2017;389:299–311.
50. Sequist L V, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine. 2011;3(75):75ra26.
51. Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2015;372:1689–99.
52. Sequist L V, Rolfe L, Allen AR. Rociletinib in EGFR -Mutated Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2015;373:578–9.
53. Lim MS, Syn N, Cho B, Soo R. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treatment Reviews. 2018; 65:1-10.
54. Pujol J-L, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O’Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2014;83:211–8.
55. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Review of Anticancer Therapy. 2013;13(6):745-758.

PDF Drljača J. et al. • MD-Medical Data 2019;11(1): 035-041